Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Harrington Discovery Institute
Areas of drug development include retinal diseases, neonatal brain injury, cancer, hypertension, atherosclerosis, pain management, resistant infections, lung disease and cardiac arrest
CLEVELAND, Dec. 11, 2013 /PRNewswire/ -- The Harrington Discovery Institute at University Hospitals (UH) Case Medical Center has announced the 2014 recipients of Harrington Scholar-Innovator Awards. The awards will support drug discovery efforts of great promise at renowned institutions across the nation.
For the past decade, American Medicine has been challenged in developing new drugs that would improve on standard of care. Lacking knowhow and industry support, many discoveries are unable to advance into the clinical realm. Aimed at addressing this critical issue, the Harrington Discovery Institute (HDI), established in 2012, is a national initiative dedicated to physician-scientists, enabling them to transform breakthrough insights into novel medicines. The institute has become the catalyst for a new national model that aligns, through structure and mission, for-profit and nonprofit resources to create a dedicated system for drug development.
The HDI opens an annual grant competition each spring to identify the nation's most promising medical breakthroughs and to accelerate their usage in patient care. In its second year, the program has chosen 11 researchers to receive Harrington Scholar-Innovator grants of up to $200,000 over two years. In addition, these Scholar-Innovators will be given access to HDI's Innovation Support Center that includes a renowned group of industry experts who are charged with helping guide drug development. Successful initiatives will have access to additional capital support to further the transition into the commercial realm.
"By identifying promising scientific discoveries and linking the researchers responsible for them with scientific and business experts in drug development, we set out to build a bridge across the 'Valley of Death' – the chasm between the laboratory and commercialization of new therapies," says the institute's director, Jonathan Stamler, MD. "We provide inventors – Harrington Scholar-Innovators of unusual promise from around the nation, who share a laser-sharp focus on advancing innovations – with biopharmaceutical expertise necessary to conquer disease."
The 2014 Harrington Scholar-Innovator grant recipients are:
Jayakrishna Ambati, MD – University of Kentucky
Darren Carpizo, MD, PhD – Rutgers Cancer Institute of New Jersey
Garret FitzGerald, MD – University of Pennsylvania
Mark Humayun, MD, PhD – University of Southern California
John Kheir, MD – Harvard University
Rahul Kohli, MD, PhD – University of Pennsylvania
Gavril Pasternak, MD, PhD – Memorial Sloan-Kettering Cancer Center
Irina Petrache, MD – Indiana University
David Rowitch, MD, PhD – University of California, San Francisco
Jean Tang, MD, PhD – Stanford University
David Wald, MD, PhD – Case Western Reserve University
"Our overall goal is to build a network of physician-scientists across the nation on the front lines of drug development," explains Dr. Stamler, who is also Director of the Institute for Transformative Molecular Medicine at the School of Medicine. "When fully scaled, the Harrington Discovery Institute plans to have the capacity to develop 40 drug therapies simultaneously every three years. It is an aggressive agenda toward changing medicine and society by enabling a global infrastructure of physician-scientists to turn their discoveries into medicines."
The Harrington Discovery Institute at UH Case Medical Center, launched in February 2012, is the not-for-profit academic medical engine of The Harrington Project for Discovery & Development – a first-of-its-kind, $250 million initiative that also includes a mission-aligned, for-profit development company, BioMotiv. Aligning these entities has, for the first time at an academic medical center, provided a comprehensive national model to advance discoveries into therapies that benefit patients.
This past year the Harrington Discovery Institute at UH Case Medical Center has developed partnerships with the American Society for Clinical Investigation, one of the nation's oldest and most respected medical honor societies, and the Alzheimer's Drug Discovery Foundation.
The Harrington Project for Discovery and Development
The Harrington Project for Discovery and Development (The Harrington Project), announced in late February 2012, is a first-of-its-kind $250M national initiative, powered by a $50 million gift from the Harrington family. It includes the Harrington Discovery Institute and a for-profit, mission-aligned development company, BioMotiv.
For more information about The Harrington Project, the Harrington Discovery Institute and the Scholar-Innovator grants program, visit: HarringtonDiscovery.org
The Creation of a Novel Commercialization Vehicle: Bringing Discoveries to Market
As part of the The Harrington Project, the Harrington Discovery Institute is aligned with a mission-driven, for-profit development company, BioMotiv, which is building a portfolio of high-value, early-stage development programs. Products are advanced to clinical proof-of-concept and then partnered. BioMotiv is dedicated to advancing discoveries by the nation's universities and medical centers.
For more information visit: BioMotiv.com.
©2012 PR Newswire. All Rights Reserved.